HilleVax, Inc. (HLVX) Dividend History

Company News

• HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & - GlobeNewswire

  HilleVax's stock plummeted after its sole clinical-stage vaccine candidate failed a phase 2b trial for norovirus-related acute gastroenteritis, leading to investor losses.

  GlobeNewswire Inc.
• HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & - GlobeNewswire

  HilleVax's stock plummeted after its sole clinical-stage vaccine candidate failed a phase 2b trial for norovirus-related acute gastroenteritis, leading to investor losses.

  GlobeNewswire Inc.
• (HLVX) - Analyzing HilleVax's Short Interest - HilleVax (NASDAQ:HLVX) - Benzinga

  HilleVax's (HLVX) short interest has risen 14.66% since its last report, with 20.02% of its shares sold short. This indicates increased bearish sentiment, as short selling is a strategy used to profit from a stock's decline.

  Benzinga
• HilleVax shares target violently slashed by Stifel after Phase 2b trial setback By Investing.com - Investing.com Australia

  Stifel downgraded HilleVax's stock from Buy to Hold and significantly reduced its price target from $34 to $3 after the company's Phase 2b trial for its HIL-214 vaccine failed to meet its primary and secondary efficacy endpoints, leading to the discontinuation of the vaccine's development for infants.

  Investing.com

  Featured Companies: SF
• Why Is HilleVax Stock Trading Lower On Monday? - HilleVax (NASDAQ:HLVX) - Benzinga

  HilleVax's investigational norovirus vaccine HIL-214 failed to meet its primary endpoint in a Phase 2b trial, leading the company to discontinue further development in infants and explore potential adult use.

  Benzinga